US Stock Insider Trading | Exicure disclosed 1 insider transaction on February 19

K-LinePoet · 2026-02-22T21:54:35+00:00

Exicure executive Miller Josh sold 8 shares on February 16, 2026, at a price of $4.08, totaling $32.64. Recently, there have been multiple insider sales, indicating active trading by company insiders. Exicure is a clinical-stage biotechnology company focused on immuno-oncology and other fields.

K-LinePoet

2026-02-22 21:54:35

Abstract generation in progress

On February 19, 2026, Exicure (XCUR) disclosed one insider trading transaction. Executive Miller Josh sold 8 shares on February 16, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Miller Josh	February 16, 2026	Sell	8	4.08	32.64
January 21, 2026	Shareholder with over 10% ownership	Exicure HiTron Inc.	January 21, 2026	Sell	258,400	4.50	1,162,700
January 20, 2026	Shareholder with over 10% ownership	Exicure HiTron Inc.	January 16, 2026	Sell	734,700	4.50	3,306,400
January 8, 2026	Shareholder with over 10% ownership	Exicure HiTron Inc.	January 7, 2026	Sell	741,300	4.50	3,335,700
December 10, 2025	Shareholder with over 10% ownership	SANGSANGIN INVESTMENT & SECURITIES CO., LTD.	December 8, 2025	Sell	433,300	8.71	3,774,300
November 19, 2025	Executive	Miller Josh	November 16, 2025	Sell	7	3.71	25.97
August 20, 2025	Executive	Miller Josh	August 16, 2025	Sell	9	6.65	59.85
May 23, 2025	Executive	Miller Josh	May 16, 2025	Sell	8	10.06	80.48
March 26, 2025	Shareholder with over 10% ownership	HiTron Systems Inc.	December 26, 2024	Buy	2,900,000	3.00	8,700,000
February 24, 2025	Executive	Miller Josh	February 16, 2025	Sell	9	10.03	90.27

[Company Profile]

Exicure, Inc. was founded on July 9, 2015. The company is a clinical-stage biotechnology firm developing therapeutics based on its proprietary spherical nucleic acid (SNA) technology for immuno-oncology, inflammatory diseases, and genetic disorders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes